This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.
Protect Your Portfolio From Volatility With 5 Low-Beta Picks
by Nalak Das
At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank as these will be less volatile than the broader market. These are: ABT, CAT, CNA, GOLF and SAFM.
OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
Top Analyst Reports for Abbott, SAP & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), SAP SE (SAP), and Freeport-McMoRan (FCX).
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
by Zacks Equity Research
Medtronic's (MDT) recent surgeries reach a milestone in the transformation of spine surgery as a result of increased accuracy and minimally invasive technique.
Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q4.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN
by Zacks Equity Research
Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
by Zacks Equity Research
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.
Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
by Zacks Equity Research
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
5 Top Ranked Stocks With Solid Sales Growth to Buy Right Now
by Swayta Shah
Sales growth is an important indicator of a company's health and ability to sustain its business. Let's check Abbott (ABT), Facebook (FB), Stanley Black & Decker (SWK), Leidos (LDOS) & Euronet (EEFT) as these might witness solid sales growth.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis
by Zacks Equity Research
In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.